Meropenem Hikma (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, leading to osmotic lysis and bacterial death. Its structure also confers stability against many β‑lactamases, extending its activity to a wide range of pathogens.

The dose of Meropenem Hikma is determined by the prescribing clinician based on the type and severity of the infection, the patient’s renal function, weight, and any relevant comorbidities. Dosage adjustments are especially important in patients with impaired kidney function to avoid accumulation and toxicity.

The pregnancy category for meropenem is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Meropenem Hikma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meropenem shares the same class mechanism as other carbapenems such as imipenem and ertapenem, offering broad‑spectrum activity. Compared with imipenem, meropenem has a lower risk of seizures and does not require co‑administration with cilastatin. Its spectrum includes many resistant Gram‑negative organisms, making it a preferred choice for severe hospital‑acquired infections.

Meropenem Hikma, supplied as a sterile powder for injection, should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing. Once reconstituted, the solution should be used promptly according to the manufacturer’s stability guidelines.

Meropenem Hikma is administered intravenously. The sterile powder is reconstituted with the appropriate diluent, then infused over a specified period, typically 15‑30 minutes, depending on the clinical protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

Serious adverse events associated with meropenem include anaphylactic reactions, seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, and significant elevations in liver enzymes. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Hikma should be avoided in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving concomitant drugs that may increase neurotoxicity.